Literature DB >> 12517939

Protection against experimental autoimmune encephalomyelitis generated by a recombinant adenovirus vector expressing the V beta 8.2 TCR is disrupted by coadministration with vectors expressing either IL-4 or -10.

Todd A Braciak1, Brian Pedersen, Judy Chin, Clay Hsiao, E Sally Ward, Igor Maricic, Alex Jahng, Frank L Graham, Jack Gauldie, Eli E Sercarz, Vipin Kumar.   

Abstract

Adenovirus vectors are increasingly being used for genetic vaccination and may prove highly suitable for intervention in different pathological conditions due to their capacity to generate high level, transient gene expression. In this study, we report the use of a recombinant adenovirus vector to induce regulatory responses for the prevention of autoimmune diseases through transient expression of a TCR beta-chain. Immunization of B10.PL mice with a recombinant adenovirus expressing the TCR Vbeta8.2 chain (Ad5E1 mVbeta8.2), resulted in induction of regulatory type 1 CD4 T cells, directed against the framework region 3 determinant within the B5 peptide (aa 76-101) of the Vbeta8.2 chain. This determinant is readily processed and displayed in an I-A(u) context, on ambient APC. Transient genetic delivery of the TCR Vbeta8.2 chain protected mice from Ag-induced experimental autoimmune encephalomyelitis. However, when the Ad5E1 mVbeta8.2 vector was coadministered with either an IL-4- or IL-10-expressing vector, regulation was disrupted and disease was exacerbated. These results highlight the importance of the Th1-like cytokine requirement necessary for the generation and activity of effective regulatory T cells in this model of experimental autoimmune encephalomyelitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12517939     DOI: 10.4049/jimmunol.170.2.765

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Homeostatic control of immunity by TCR peptide-specific Tregs.

Authors:  Vipin Kumar
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

2.  Global expression profiling of peripheral Qa-1-restricted CD8αα+TCRαβ+ regulatory T cells reveals innate-like features: implications for immune-regulatory repertoire.

Authors:  Shaohsuan S Fanchiang; Radu Cojocaru; Mohammad Othman; Ritu Khanna; Matthew J Brooks; Trevor Smith; Xiaolei Tang; Igor Maricic; Anand Swaroop; Vipin Kumar
Journal:  Hum Immunol       Date:  2011-08-17       Impact factor: 2.850

3.  TAP1-/- mice present oligoclonal BV-BJ expansions following the rejection of grafts bearing self antigens.

Authors:  Idania Marrero; Donald Huffman; Jorge Kalil; Eli E Sercarz; Verônica Coelho
Journal:  Immunology       Date:  2006-08       Impact factor: 7.397

4.  Viewing Autoimmune Pathogenesis from the Perspective of Antigen Processing and Determinant Hierarchy.

Authors:  Kamal D Moudgil
Journal:  Crit Rev Immunol       Date:  2020       Impact factor: 2.214

5.  CD8alpha+ dendritic cells prime TCR-peptide-reactive regulatory CD4+FOXP3- T cells.

Authors:  Trevor R F Smith; Igor Maricic; Francesco Ria; Susan Schneider; Vipin Kumar
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

6.  Involvement of IFN-γ and perforin, but not Fas/FasL interactions in regulatory T cell-mediated suppression of experimental autoimmune encephalomyelitis.

Authors:  Tara Beeston; Trevor R F Smith; Igor Maricic; Xiaolei Tang; Vipin Kumar
Journal:  J Neuroimmunol       Date:  2010-08-12       Impact factor: 3.478

7.  T-lymphocytes mediate left ventricular fibrillar collagen cross-linking and diastolic dysfunction in mice.

Authors:  Qianli Yu; Randy Vazquez; Sherma Zabadi; Ronald R Watson; Douglas F Larson
Journal:  Matrix Biol       Date:  2010-06-25       Impact factor: 11.583

8.  The effects of intradermal vaccination with DNA encoding for the T-cell receptor on the induction of experimental autoimmune encephalomyelitis in B10.PL mice.

Authors:  Soon Seog Kwon; Nachsung Kim; Tae-June Yoo
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

Review 9.  Vaccines for multiple sclerosis: progress to date.

Authors:  Jorge Correale; Mauricio Farez; Wendy Gilmore
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.